Drug Delivery Devices for Innovative Parenterals and Biosimilars: Patient-Centered Technical and Business Opportunities

10:10 - 10:45

  • Innovative Biologics versus Biosimilars - understanding and delivering on emerging customer needs
  • Smart devices – who is the customer
  • Changing biologics portfolios inline with new device technologies
  • Intravitreal injections as special challenge with recent advancements

Corinna Sonderegger, Head Portfolio Management Device Development & Commercialization, Novartis